Analyst consensus rating
Axsome Therapeutics Analyst Rating: Strong Buy
Direct answer
Axsome Therapeutics's consensus rating is Strong Buy.
21 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $285.42.
Forecast evidence checked September 9, 2026.
Get free Axsome Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $207.82
- Average price target
- $285.42
- High price target
- $380.00
- Low price target
- $246.00
- Low target gap
- +18.4%
- Target upside
- +37.3%
- High target gap
- +82.9%
- Target range width
- 64.5%
- Consensus rating
- Strong Buy
- Analysts
- 21
- Evidence date
- September 9, 2026
- Valid through
- September 16, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Axsome Therapeutics?
Axsome Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $285.42.
How far are Axsome Therapeutics's low and high targets from the recorded price?
The low target implies +18.4%, while the high target implies +82.9%.
How many analysts are included in Axsome Therapeutics's consensus?
The verified consensus includes 21 analysts.
How is Axsome Therapeutics's target upside or downside calculated?
The average target of $285.42 is divided by the recorded price of $207.82, then one is subtracted to produce +37.3%. This does not guarantee a future return.
When was Axsome Therapeutics's analyst forecast verified?
The data was verified on 2026-09-09. The dataset is valid through 2026-09-16.